Sucrosomial iron? Not so fast
European Journal of Cardio-Thoracic Surgery · 06.05.2025 · 67 (5)
DOI: 10.1093/ejcts/ezaf067 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Cardio-Thoracic Surgery, online erschienen am 27.05.2025. Verfasst von Salvador Payán-Pernía und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Hospital Universitario Virgen del Rocío, Sevilla, Spain. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
To the Editor, In the 2024 EACTS/EACTAIC guidelines on patient blood management in adult cardiac surgery, the authors state that ‘oral iron supplementation with a Sucrosomial formulation prior to cardiac surgery should be considered in iron-depleted anaemic patients’, substituting traditional iron formulations that have long been the standard treatment for iron-deficiency (ID) anaemia [1]. This specific recommendation for Sucrosomial iron (SI) is based exclusively on a single-centre study, in which one of the authors of the guidelines was the principal investigator [2]. While a post hoc analysis showed the greatest haemoglobin increase in anaemic patients [1], the study administered SI regardless of anaemia or ID. Although this approach may offer practical advantages, it contradicts the best clinical standards and the guidelines’ own recommendation to determine the aetiology of anaemia, which will not result from ID in 50% of anaemic patients undergoing cardiac surgery [3]. Sucrosomial iron is not recognized by the European Medicines Agency or national medicines agencies as a medication, but it is considered a nutritional supplement. Consequently, the evidence for its benefit and safety in treating ID has not undergone the rigorous evaluation of these agencies and has not been authorized for this use. Recent studies show that lower single daily doses of ferrous salts (40–80 mg), even when taken on alternate days, improve efficacy by maximizing fractional iron absorption [4]. These lower doses also reduce gastrointestinal side effects, which are associated with unabsorbed iron [4]. Despite the innovative potential of SI, high-quality studies comparing it with ferrous salts at the new low-dose standard are lacking [5]. The absorption of SI is mostly hepcidin-independent. Although some patients undergoing cardiac surgery may exhibit chronic inflammation that limits the absorption of traditional iron formulations due to increased hepcidin levels, this assumption should not justify systematically discarding such treatment if there is sufficient time before surgery (>4 weeks). Not all patients with ID will have inflammation, which can be mild, and ID itself counteracts the hepcidin increase associated with inflammation [4]. For example, in an observational study of 50 patients with ID anaemia following percutaneous coronary intervention, 3 months of treatment with either SI or ferrous sulphate resulted in a similar haemoglobin increase (2 g/dl) [5]. With as little time as 1 or 2 days before cardiac surgery, a single dose of intravenous iron and another of erythropoietin can reduce transfusion and the hospital stay in patients with ID anaemia without adding adverse effects [6]. Although SI may be presented as cost-effective, it must be noted that it is not covered by public health systems, and its cost (∼€25–30 for 30 tablets in countries such as Spain or Italy; 2 capsules/day were given in the cited study [2]) must be fully borne by the patient, who should be adequately informed beforehand. In conclusion, we consider that SI should not be adopted as a standard alternative to low-dose oral ferrous salts at present, and that intravenous iron should be the preferred option when the latter proves ineffective or when time to surgery is limited. Additionally, the cost of SI to the patient should be taken into account. None declared. Conflict of interest: Salvador Payán-Pernía reports honoraria for lectures from Amgen, Sandoz and Sysmex, and travel grants from Vifor Pharma. Esther Méndez Arias reports travel grants from Vifor Pharma. María J. Colomina reports honoraria for lectures from Vifor Pharma, Fresenius and Baxter, and travel grants from Vifor Pharma. José Antonio García-Erce reports honoraria for lectures from CSL-Behring, Italfarmaco, Octapharma and Roche. He also reports scientific activities sponsorship from Pierre Fabre, Roche, Sandoz and Zambon, and travel grants from Terumo and Vifor Pharma. We would like to thank Dr Rafael Sádaba for his critical review.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
- Instituto de Biomedicina de Sevilla (IBiS)-CSIC, Universidad de Sevilla, Sevilla, Spain.
- Department Anaesthesia, Pain Medicine and Critical Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- Department of Pharmacy, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
- Perfusion Unit, Cardiac Surgery, Hospital Universitario de Navarra, Pamplona, Spain.
- Department of Cardiovascular Surgery, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
ORCID-Profile: Salvador Payán-Pernía, Esther Méndez Arias, José Luis Pérez Blanco, Miguel Ángel Navarro-García, María J Colomina, José Antonio García-Erce
Zitieren
APA
Payán-Pernía, S., Méndez Arias, E., Pérez Blanco, J. L., Navarro-García, M. Á., Martínez-León, J. B., Colomina, M. J., & García-Erce, J. A. (2025). Sucrosomial iron? Not so fast. European Journal of Cardio-Thoracic Surgery, 67(5). https://doi.org/10.1093/ejcts/ezaf067
Vancouver
Payán-Pernía S, Méndez Arias E, Pérez Blanco JL, Navarro-García MÁ, Martínez-León JB, Colomina MJ, et al. Sucrosomial iron? Not so fast. European Journal of Cardio-Thoracic Surgery. 2025;67(5). doi:10.1093/ejcts/ezaf067
BibTeX
@article{PaynPerna2025,
author = {Payán-Pernía, Salvador and Méndez Arias, Esther and Pérez Blanco, José Luis and Navarro-García, Miguel Ángel and Martínez-León, Juan B and Colomina, María J and García-Erce, José Antonio},
title = {Sucrosomial iron? Not so fast},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2025},
volume = {67},
number = {5},
doi = {10.1093/ejcts/ezaf067}
}
EUVIMED